Clinical Trials Using Gallium Ga 68-labeled PSMA-11

Clinical trials are research studies that involve people. The clinical trials on this list are studying Gallium Ga 68-labeled PSMA-11. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-23 of 23
  • Fluciclovine F18 or Gallium Ga 68-labeled PSMA-11 PET / CT in Enhancing Outcomes in Patients with Prostate Adenocarcinoma

    This phase II trial studies how well a positron emission tomography (PET) / computed tomography (CT) scan using fluciclovine F18 compared with a PET / CT scan with gallium Ga 68-labeled PSMA-11 works in planning radiation treatments and enhancing outcomes in patients with prostate adenocarcinoma. Fluciclovine F18 and gallium Ga 68-labeled PSMA-11 are types of tracers, called radiotracers, that are injected and can accumulate in tumor cells to develop images of them during a PET / CT scan. It is not yet known whether giving fluciclovine F18 or gallium Ga 68-labeled PSMA-11 may work better in planning radiation treatments and enhancing outcomes in patients with prostate adenocarcinoma.
    Location: 4 locations

  • 68Ga-RM2 and 68Ga-PSMA-11 PET / MRI for the Treatment of Patients with Low-Risk and Intermediate-Risk Prostate Cancer Scheduled for High-Dose Rate Brachytherapy

    This phase II trial studies how well 68Ga-RM2 and 68Ga-PSMA-11 PET / MRI works for the treatment of patients with low-risk and intermediate-risk prostate cancer scheduled for high-dose rate brachytherapy. Diagnostic procedures, such as 68Ga-RM2 and 68Ga-PSMA-11 PET / MRI, may help find and diagnose prostate cancer and assess response to therapy. This study may help researchers determine if the combination of imaging agents 68Ga RM2 and 68Ga PMSA11 work better in assessing response to therapy than standard imaging or biopsy.
    Location: Stanford Cancer Institute Palo Alto, Palo Alto, California

  • 68Ga-HBED-CC PSMA-PET / MRI for the Definition of Radiation Treatment in Patients with Prostate Cancer

    This phase II trial studies the effect of 68Ga-HBED-CC PSMA-PET / MRI in defining the best placement of radiation in patients with prostate cancer undergoing radiation therapy. Diagnostic procedures, such as 68Ga-HBED-CC PSMA-PET / MRI, may help design the radiation treatment plan so that the entire prostate receives the prescribed dose of radiation and, in addition, the visible tumor as defined by the scans receives hot spots. Hot spots are the areas that receive above the dose of prescription simply due to the nature of radiation therapy. All radiation plans have hot spots. This trial focuses the hot spots on certain regions determined by the scans where the visible tumor is located as opposed to the current practice where hot spot regions are randomly located in the target area.
    Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

  • A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer

    The purpose of this study is to find the highest dose level of study drug, CTT1403, that can be safely administered to patients with metastatic castration resistant prostate cancer (mCRPC).
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • Using PSMA-PET / MRI to Guide Cyberknife-Delivered Stereotactic Body Radiation Therapy for Favorable Risk Prostate Cancer

    This phase II trial studies the effect of using PSMA-PET / MRI to guide cyberknife-delivered stereotactic body radiation therapy in favorable risk prostate cancer patients. Diagnostic procedures, such as PSMA-PET / MRI may help design the radiation treatment plan so that the entire prostate receives the prescribed dose of radiation and, in addition, the visible tumor as defined by the scans receives hot spots. Hot spots are areas that receive above the dose of prescription simply due to the nature of radiation therapy. The imaging techniques in this study help focus the hot spots on certain regions determined by the scans where the visible tumor is located as opposed to the current practice where hot spot regions are randomly located in the target area. PSMA-PET / MRI may help better guide stereotactic body radiotherapy and improve treatment outcomes for future patients with prostate cancer.
    Location: See Clinical Trials.gov

  • 68Ga-PSMA-11 PET / CT Scan in Detecting Tumor Location and Size in Patients with Prostate Cancer

    This early phase II trial studies how well 68Ga-PSMA-11 positron emission tomography (PET) / computed tomography (CT) scan works in detecting tumor location and size in patients with prostate cancer. 68Ga-PSMA-11 is a radioactive imaging agent that seeks to identify prostate cancer cells that have a specific protein target called prostate-specific membrane antigen on their surface. A 68Ga-PSMA-11 PET / CT scan may help doctors to better detect the location, extent, and characteristics of tumor, allowing improved planning of subsequent therapy.
    Location: Indiana University / Melvin and Bren Simon Cancer Center, Indianapolis, Indiana

  • Serial PSMA PET Scans for the Imaging of Newly Diagnosed, Progressive, or Metastatic Prostate Cancer

    This phase II / III trial studies how well serial PSMA PET scans work in imaging patients with prostate cancer that is newly diagnosed, growing, spreading, or getting worse (progressive), or has spread to other places in the body (metastatic). PSMA PET scans use radiation to make images of tumors. Serial PSMA PET scans may work better at showing the PSMA protein, which is located on many prostate cancer cells, and in assessing treatment response in patients with prostate cancer compared to the usual imaging methods.
    Location: 7 locations

  • Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET / CT Imaging in Patients with Metastatic Castration-Resistant Prostate Cancer

    This trial studies the effect of androgen receptor signaling inhibitors on 68Ga-PSMA-11 PET / CT imaging in patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). Diagnostic procedures, such as 68Ga-PSMA-11 PET / CT, may help in learning how well androgen receptor signaling inhibitors work in killing castration-resistant prostate cancer cells and allow doctors to plan better treatment.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • 68Ga-PSMA-11 PET for the Diagnosis of Biochemically Recurrent Prostate Cancer

    This phase I trial studies the side effects of 68GA-PSMA-11 PET imaging in patients with prostate cancer that has come back (recurrent). Gallium (68Ga) is a radiotracer that binds to a molecule, PSMA, that is found in abundance on most prostate cancer cells. PSMA is short for ‘prostate specific membrane antigen’. Diagnostic procedures, such as 68GA-PSMA-11 PET imaging, may help measure a patient's response to earlier treatment, and may help plan the best treatment for prostate cancer.
    Location: City of Hope Comprehensive Cancer Center, Duarte, California

  • An Investigational Scan (68Ga PSMA-11 PET / CT) for Enhancing the Diagnosis of Primary or Metastatic Prostate Cancer

    This phase II trial investigates how well 68Ga PSMA-11 PET / CT scan works in enhancing the diagnosis of prostate cancer that is primary or has spread to other places in the body (metastatic). 68Ga PSMA-11 is a radioactive drug that carries a small amount of radiation that can be detected by the PET / CT scan. Diagnostic procedures, such as 68Ga PSMA-11 PET / CT, may find and diagnose prostate cancer and any metastasis that other imaging techniques have not identified.
    Location: UT Southwestern / Simmons Cancer Center-Dallas, Dallas, Texas

  • 68Ga-PSMA-11 and 68Ga-RM2 PET / MRI in Assessing Response in Patients with Prostate Cancer Undergoing HIFU Therapy

    This phase I / II trial studies how well 68Ga-PSMA-11 and 68Ga-RM2 positron emission tomography (PET) / magnetic resonance imaging (MRI) work in assessing response in patients with prostate cancer who are undergoing high intensity focused ultrasound (HIFU) local therapy. Diagnostic procedures, such as 68Ga-PSMA-11 PET / MRI and 68Ga-RM2 PET / MRI, may help measure a patient's response to earlier treatment. This study is being done to see if the combination of imaging agents 68Ga-PSMA-11 and 68Ga-RM2 work better at assessing response to therapy compared to standard imaging or biopsy.
    Location: Stanford Cancer Institute Palo Alto, Palo Alto, California

  • 68Ga-PSMA PET in Diagnosing Metastasis in Patients with Ovarian Cancer

    This trial studies how well gallium Ga 68-labeled prostate specific membrane antigen (PSMA)-11 (68Ga-PSMA) positron emission tomography (PET) works in patients with ovarian cancer to detect whether the tumor has spread to other places in the body (metastasis). 68Ga-PSMA is a radioactive substance that binds to blood vessels around the ovarian cancer and can be imaged using PET. Diagnostic procedures, such as PET, may help find and diagnose find out how far the disease has spread.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • 68Ga-RM2 PET / MRI Scan and 68Ga-RM2 PET / MRI Scan in Imaging Patients with Suspected Prostate Cancer

    This phase II trial studies how well 68Ga-PSMA-11 positron emission tomography (PET) / magnetic resonance imaging (MRI) scan and 68Ga-RM2 PET / MRI scan work in imaging patients with suspected prostate cancer. Diagnostic procedures, such as 68Ga-PSMA-11 PET / MRI scan and 68Ga-RM2 PET / MRI scan, may help find and diagnose prostate cancer.
    Location: Stanford Cancer Institute Palo Alto, Palo Alto, California

  • Gallium-68 PSMA-11 PET / CT for the Diagnosis of Biochemically Recurrent Prostate Cancer

    This phase II trial studies how well gallium-68 PSMA-11 PET / CT works for the diagnosis of prostate cancer with rising PSA following prostatectomy or radiation therapy (biochemically recurrent). Gallium-68 PSMA-11 is a radioactive tracer. PET / CT scans reveal information about both the structure and function of cells and tissues in the body during a single imaging session using a radioactive compound. This trial is being done to see if gallium-68 PSMA-11 PET / CT scan works better in diagnosing prostate cancer compared to standard C-11 choline PET / CT scans.
    Location: Mayo Clinic in Rochester, Rochester, Minnesota

  • 68GA-PSMA Fusion PET / MRI in Diagnosing Patients with Prostate Cancer

    This phase II trial studies how well 68GA-PSMA fusion PET / MRI works in finding prostate lesions in patients with prostate cancer. Radioactive drugs, such as 68GA-PSMA, are taken up by cancer cells. Diagnostic procedures, such as PET or MRI, may help find and diagnose prostate cancer or find out how far the disease has spread. Giving 68GA-PSMA fusion PET / MRI may work better in diagnosing patients with prostate cancer.
    Location: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

  • Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients with Thyroid Cancer

    This phase II trial studies how well Gallium-68 prostate specific membrane antigen positron emission tomography (PET) work in diagnosing patients with thyroid cancer. Diagnostic procedures, such as 68Ga-PSMA PET, may more accurately diagnose thyroid cancer and find out how far the disease has spread.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • Gallium Ga 68-labeled PSMA-11 PET / CT in Diagnosing Participants with Biochemical Recurrent Prostate Cancer

    This phase II trial studies how well gallium Ga 68-labeled prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET) / computed tomography (CT) works in diagnosing patients with prostate cancer and with rising prostate specific antigen after treatment. Ga-68 PSMA is an imaging drug that binds to prostate tumor cells and can be imaged using PET. Diagnostic procedures, such as gallium Ga 68-labeled PSMA-11 PET / CT, may help find the presence of prostate cancer.
    Location: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

  • Gallium Ga 68-labeled PSMA-11 PET / CT in Diagnosing Participants with Intermediate to High-Risk Prostate Cancer

    This pilot phase II / III trial studies how well gallium Ga 68-labeled PSMA-11 positron emission tomography / computed tomography (PET / CT) works in diagnosing participants with intermediate to high-risk prostate cancer. Diagnostic procedures, such as gallium Ga 68-labeled PSMA-11 PET / CT, may help detect pelvic nodal disease in participants with prostate cancer.
    Location: University of Iowa / Holden Comprehensive Cancer Center, Iowa City, Iowa

  • Gallium Ga 68-labeled PSMA-11 PET / MRI in Diagnosing Participants with PSMA-positive Tumors

    This pilot trial studies how well gallium Ga 68-labeled prostate-specific membrane antigen (PSMA)-11 positron-emission tomography (PET) / magnetic resonance imaging (MRI) works in diagnosing participants with PSMA-positive tumors. Gallium Ga 68-labeled PSMA- is an imaging drug that binds to tumor cells and can be imaged using PET / MRI. Diagnostic procedures, such as gallium Ga 68-labeled PSMA-11 PET / MRI, may help find the presence of cancer.
    Location: Case Comprehensive Cancer Center, Cleveland, Ohio

  • 68Ga PSMA-HBED-CC PET / CT in Imaging Patients with Metastatic Prostate Cancer

    This pilot clinical trial studies how well 68Ga PSMA-HBED-CC positron emission tomography / computed tomography (PET / CT) works in imaging patients with prostate cancer that has spread to other parts of the body. Diagnostic procedures, such as 68Ga PSMA-HBED-CC PET / CT, may help find and diagnose metastatic prostate cancer and find out how far the disease has spread.
    Location: University of Iowa / Holden Comprehensive Cancer Center, Iowa City, Iowa

  • 68Ga-PSMA-11 PET / MRI in Finding Tumors in Patients with Intermediate or High-Risk Prostate Cancer Undergoing Surgery

    This phase II / III trial studies Ga 68-PSMA-11 positron emission tomography / magnetic resonance imaging (PET / MRI) in finding tumors in patients with prostate cancer undergoing surgery that tend to spread quickly (intermediate-risk) or is likely to come back or spread (high-risk). Diagnostic procedures, such as PET / MRI, may help find and diagnose prostate cancer and find out how far the disease has spread. Radioactive drugs, such Ga 68-PSMA-11, binds to tumor cells that have specific receptors, and may allow doctors to see smaller tumors than the standard of care contrast-enhanced computed tomography (CT) or MRI scan.
    Location: Stanford Cancer Institute Palo Alto, Palo Alto, California

  • Gallium Ga 68-labeled PSMA-11 PET / CT in Detecting Prostate Cancer Recurrence in Patients with Elevated PSA after Initial Treatment

    This phase II / III trial studies how well gallium Ga 68-labeled prostate specific membrane antigen (PSMA)-11 positron emission tomography (PET) / computed tomography (CT) works in detecting prostate cancer that may have come back in patients with elevated prostate-specific antigen (PSA) after initial treatment. A rise in blood level of PSA, a protein made by the prostate, after treatment with surgery or radiation in patients without symptoms indicates that the cancer may have come back (recurrence). PSA however cannot determine whether the disease is located only in the prostate or other places in the body. 68Ga-PSMA-11 is a radioactive tracer that targets and specifically binds to tumor cells expressing PSA making them lighting up. PET and CT make computerizing pictures of areas inside the body where the radioactive substance is lighting up. 68Ga-PSMA-11 PET / CT may be able to see smaller tumors than standard imaging and may help determine whether prostate cancer has come back and where it is in the body.
    Location: Stanford Cancer Institute Palo Alto, Palo Alto, California

  • 68Ga-FAPI-46 (+ / - 68Ga-PSMA-11) PET biodistribution in Patients with Non-Prostate Cancers

    This exploratory study uses a new imaging technique called FAPi PET / CT to determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulate in normal and cancer tissues in patients with various cancer (non-prostate). The research team also want to know whether what they see on PET / CT images represents the tumor tissue being excised from the patient’s body. The research team is also interested to investigate another new imaging technique called PSMA PET / CT. Participants will be invited to undergo a second PET / CT scan, with the PSMA tracer (68Ga-PSMA-11). This is not required but just an option for volunteer patients. Patients can decide to have only the FAPI PET / CT scan. FAP stands for Fibroblast Activation Protein. FAP is produced by cells that surround tumors. The function of FAP is not well understood but imaging studies have shown that FAP can be detected with FAPI PET / CT. Imaging FAP with FAPI PET / CT may in the future provide additional information about various cancers. PSMA stands for Prostate Specific Membrane Antigen. This name is incorrect as PSMA is also found in many other cancers. The function of PSMA is not well understood but imaging studies have shown that PSMA can be detected with PET in many non-prostate cancers.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California